替奈普酶静脉溶栓后联合替罗非班治疗老年急性缺血性卒中的临床效果研究
CSTR:
作者:
作者单位:

(邯郸市第一医院神经内二科,河北 邯郸 056004)

作者简介:

通讯作者:

中图分类号:

基金项目:

邯郸市科学技术研究与发展计划(23422083295)


Efficacy of tirofiban after intravenous thrombolysis with Tenecteplase in elderly patients with acute ischemic stroke
Author:
Affiliation:

(Neurology Department 2, Handan First Hospital, Handan 056004, Hebei Province, China)

Fund Project:

This work was supported by Plan Project of Handan Science and Technology Research and Development(23422083295).

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 分析替奈普酶静脉溶栓后联合替罗非班治疗老年急性缺血性卒中(AIS)的临床效果。方法 收集2023年1月至2024年12月邯郸市第一医院收治的替奈普酶静脉溶栓治疗的168例老年中等血管闭塞AIS患者的临床资料,其中82例患者在静脉溶栓后24 h内未给予抗血小板治疗(对照组),86例患者在静脉溶栓后2h排除出血并给予替罗非班静脉泵注24 h治疗(替罗非班组)。在溶栓后3d行头颅影像学检查评估血管再通情况,记录两组溶栓前,溶栓后1、7、14d神经功能缺损[美国国立卫生研究院卒中量表(NIHSS)]变化及早期神经功能恶化(END)发生率,比较两组溶栓前及溶栓后14d实验室指标[活化部分凝血活酶时间(APTT)、纤维蛋白原(FIB)、红细胞比容(HCT)、血小板计数(PLT)]差异,记录两组溶栓后3d内脑出血转化(HT)、系统性出血事件发生情况,在溶栓后90 d使用改良Rankin量表(mRS)评估两组预后状况。采用SPSS 24.0软件进行数据分析。根据数据类型,组间比较分别采用t检验、方差分析、χ2检验及Fisher精确概率法。结果 使用倾向性评分匹配消除不平衡变量,得到78对资料均衡的患者,即替罗非班组与对照组各78例。替罗非班组血管再通程度及血管再通率均高于对照组[75.64%(59/78)和58.97%(46/78),P<0.05]。两组溶栓后NIHSS评分均较溶栓前降低(P<0.05),且溶栓后14 d NIHSS评分低于溶栓后1、7 d(P<0.05),溶栓后7 d NIHSS评分低于溶栓后1 d(P<0.05);替罗非班组溶栓后1、7、14 d NIHSS评分及END发生率(2.56%2/78和11.54% 9/78,P<0.05)均低于对照组。两组溶栓前后APTT、FIB、HCT、PLT组内及组间比较,差异均无统计学意义(均P>0.05)。替罗非班组及对照组HT发生率和系统性出血事件总发生率比较,差异均无统计学意义(P>0.05)。溶栓后90 d,替罗非班组mRS≤2分占比高于对照组,差异有统计学意义[92.31%(72/78)和80.77%(63/78),P<0.05]。结论 替奈普酶静脉溶栓后早期联合替罗非班治疗老年中等血管闭塞AIS疗效及安全性良好,在促进血管再通、减少END及改善近期预后方面具有一定优势。

    Abstract:

    Objective To analyze the application of tirofiban after intravenous thrombolysis with Tenecteplase in elderly patients with acute ischemic stroke (AIS). Methods The clinical data of 168 elderly patients with moderate vascular occlusion AIS who received intravenous thrombolysis with Tenecteplase in Handan First Hospital from January 2023 to December 2024 were collected. Among them, 82 patients (control group) did not receive antiplatelet therapy within 24 h after intravenous thrombolysis, and 86 (tirofiban group) were given tirofiban intravenous infusion for 24 h after excluding those with bleeding 2 h after intravenous thrombolysis. Cranial imaging examination was performed at 3 d after thrombolysis to assess vascular recanalization. Neurological deficits [national institutes of health stroke scale (NIHSS)] and incidence rate of early neurological deterioration (END) were recorded in both groups before thrombolysis and at 1,7 and 14 d after thrombolysis. The differences in laboratory indexes [activated partial thromboplastin time (APTT), fibrinogen (FIB), hematocrit (HCT), platelet count (PLT)] before thrombolysis and at 14 d after thrombolysis were compared between the two groups. The occurrence of cerebral hemorrhage transformation (HT) and systemic bleeding within 3 d after thrombolysis were recorded. The modified Rankin scale (mRS) was used to assess the prognosis in the two groups at 90 d after thrombolysis. SPSS statistics 24.0 was used for statistical analysis. Data comparison between two groups was perfomed using t test, analysis of Variance, χ2 test or Fisher′s exact probability test depending on data type. Results Using propensity score matching to eliminate unbalanced variables, 78 well-matched patients were obtained, i.e., 78 patients each in the tirofiban group and the control group. The degree of vascular recanalization and the recanalization rate in the tirofiban group were higher than those in the control group [75.64% (59/78) vs 58.97% (46/78); P<0.05]. The NIHSS scores after thrombolysis decreased compared with before thrombolysis in both groups (P<0.05), the NIHSS scores at 14 d after thrombolysis were lower than those at 1 and 7 d after thrombolysis (P<0.05), and the NIHSS scores at 7 d after thrombolysis was lower than those at 1 d after thrombolysis (P<0.05). The NIHSS scores at 1,7 and 14 d after thrombolysis and the incidence rate of END [2.56% (2/78) vs 11.54% (9/78), P<0.05] in the tirofiban group were lower than those in the control group. There were no statistical differences in APTT, FIB, HCT and PLT within groups before and after thrombolysis and between the two groups (all P>0.05). The differences in incidence rates of HT and the total incidence rates of systemic bleeding events between the tirofiban group and the control group were not statistically significant (P>0.05). At 90 d after thrombolysis, the proportion of patients with mRS ≤ 2 points in the tirofiban group was higher than that in the control group [92.31% (72/78) vs 80.77% (63/78)], and the difference was statistically significant (P<0.05). Conclusion Early combination of tirofiban after intravenous thrombolysis with Tenecteplase demonstrateds good efficacy and safety in the treatment of elderly AIS patients with moderate vascular occlusion, showing certain advantages in promoting vascular recanalization, reducing END, and improving short-term prognosis.

    参考文献
    相似文献
    引证文献
引用本文

李晓雪,姜晓菊.替奈普酶静脉溶栓后联合替罗非班治疗老年急性缺血性卒中的临床效果研究[J].中华老年多器官疾病杂志,2026,25(5):383-387
DOI:10.11915/j. issn.1671-5403.2026.05.078

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2025-05-13
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2026-05-26
  • 出版日期:
文章二维码